Hepatocellular carcinoma is a common malignant tumor with limited treatment options. At present, immunotherapy has limited efficacy in liver cancer cells. Membrane associated protein A1 is a protein associated with inflammation, immunity, and tumors. However, the role of membrane associated protein A1 in the development of liver tumors is still unclear.
The research team led by Song Zhenghui from the Hospital of Traditional Chinese and Western Medicine at Southern Medical University explored the feasibility of using membrane associated protein A1 as a therapeutic target for hepatocellular carcinoma. Through multiple dimensions and methods, they found that membrane associated protein A1 may be an independent prognostic factor for hepatocellular carcinoma and demonstrated its clinical translational significance in immunotherapy for hepatocellular carcinoma.
The study was published on May 15, 2023, in the international journal Biochemical Pharmacology, titled Targeting of Annexin A1 in Tumor associated Macrophages as a therapeutic strategy for hepatocellular carcinoma.
IF=6.1 (2022)。
Figure 1. The study was published in the international journal Biochemical Pharmacology
图2.文章中图片
Figure 3. Cell culture in this study was conducted using Opsey fetal bovine serum